{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:58:40Z","timestamp":1792108720182,"version":"4.4.0"},"reference-count":70,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ANGLE plc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>The study of molecular drivers of cancer is an area of rapid growth and has led to the development of targeted treatments, significantly improving patient outcomes in many cancer types. The identification of actionable mutations informing targeted treatment strategies are now considered essential to the management of cancer. Traditionally, this information has been obtained through biomarker assessment of a tissue biopsy which is costly and can be associated with clinical complications and adverse events. In the last decade, blood-based liquid biopsy has emerged as a minimally invasive, fast, and cost-effective alternative, which is better suited to the requirement for longitudinal monitoring. Liquid biopsies allow for the concurrent study of multiple analytes, such as circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), from a single blood sample. Although ctDNA assays are commercially more advanced, there is an increasing awareness of the clinical significance of the transcriptome and proteome which can be analysed using CTCs. Herein, we review the literature in which the microfluidic, label-free Parsortix\u00ae system is utilised for CTC capture, harvest and analysis, alongside the analysis of ctDNA from a single blood sample. This detailed summary of the literature demonstrates how these two analytes can provide complementary disease information.<\/jats:p>","DOI":"10.3390\/cimb46010050","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T08:57:32Z","timestamp":1705481852000},"page":"773-787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix\u00ae System"],"prefix":"10.3390","volume":"46","author":[{"given":"Gabrielle","family":"Wishart","sequence":"first","affiliation":[{"name":"ANGLE plc, Guildford GU2 7QB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9797-0773","authenticated-orcid":false,"given":"Amy","family":"Templeman","sequence":"additional","affiliation":[{"name":"ANGLE plc, Guildford GU2 7QB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Hendry","sequence":"additional","affiliation":[{"name":"ANGLE plc, Guildford GU2 7QB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Miller","sequence":"additional","affiliation":[{"name":"ANGLE plc, Guildford GU2 7QB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Pailhes-Jimenez","sequence":"additional","affiliation":[{"name":"ANGLE plc, Guildford GU2 7QB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"ref_1","unstructured":"The World Health Organization (2023, September 18). Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tips.2022.02.005","article-title":"Circulating Tumor Cells in Precision Medicine: Challenges and Opportunities","volume":"43","author":"Rupp","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling Tumour Heterogeneity by Single-Cell Profiling of Circulating Tumour Cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tlcr-20-189","article-title":"Future Perspectives from Lung Cancer Pre-Clinical Models: New Treatments Are Coming?","volume":"9","author":"Bersani","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"698551","DOI":"10.3389\/fonc.2021.698551","article-title":"Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (CtDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer","volume":"11","author":"Kong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5858\/arpa.2019-0559-RA","article-title":"Liquid Biopsy in Breast Cancer: A Focused Review","volume":"145","author":"Tay","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1634\/theoncologist.2020-0246","article-title":"State of the Science and Future Directions for Liquid Biopsies in Drug Development","volume":"25","author":"Narayan","year":"2020","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy","volume":"6","author":"Pantel","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13073-020-00728-3","article-title":"Tracking Cancer Progression: From Circulating Tumor Cells to Metastasis","volume":"12","author":"Aceto","year":"2020","journal-title":"Genome Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12564","DOI":"10.1038\/s41598-020-69432-x","article-title":"Evaluating the Quantity, Quality and Size Distribution of Cell-Free DNA by Multiplex Droplet Digital PCR","volume":"10","author":"Alcaide","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sant, M., Bernat-Peguera, A., Felip, E., and Margel\u00ed, M. (2022). Role of CtDNA in Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14020310"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical Relevance of Blood-Based CtDNA Analysis: Mutation Detection and Beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","article-title":"The Main Sources of Circulating Cell-Free DNA: Apoptosis, Necrosis and Active Secretion","volume":"157","author":"Hu","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","article-title":"Practical Recommendations for Using CtDNA in Clinical Decision Making","volume":"619","author":"Cohen","year":"2023","journal-title":"Nature"},{"key":"ref_15","unstructured":"(2022). FDA, List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)."},{"key":"ref_16","unstructured":"(2024, January 09). Premarket Approval (PMA) Cobas EGFR Mutation Test, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P120019s018."},{"key":"ref_17","unstructured":"(2024, January 09). Premarket Approval (PMA) Cobas Mutation Test 2, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P150047."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor Self-Seeding by Circulating Cancer Cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tretyakova, M.S., Menyailo, M.E., Schegoleva, A.A., Bokova, U.A., Larionova, I.V., and Denisov, E.V. (2022). Technologies for Viable Circulating Tumor Cell Isolation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415979"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1158\/0008-5472.CAN-15-0145","article-title":"Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy","volume":"75","author":"Maheswaran","year":"2015","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Deng, Z., Wu, S., Wang, Y., and Shi, D. (2022). Circulating Tumor Cell Isolation for Cancer Diagnosis and Prognosis. eBioMedicine, 83.","DOI":"10.1016\/j.ebiom.2022.104237"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Descamps, L., Le Roy, D., and Deman, A.-L. (2022). Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23041981"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bhat, M.P., Thendral, V., Uthappa, U.T., Lee, K.-H., Kigga, M., Altalhi, T., Kurkuri, M.D., and Kant, K. (2022). Recent Advances in Microfluidic Platform for Physical and Immunological Detection and Capture of Circulating Tumor Cells. Biosensors, 12.","DOI":"10.3390\/bios12040220"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-Mesenchymal Transition in Cancer: A Historical Overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cyto.a.23571","article-title":"The ParsortixTM Cell Separation System\u2014A Versatile Liquid Biopsy Platform","volume":"93","author":"Miller","year":"2018","journal-title":"Cytometry A"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Cohen, E.N., Jayachandran, G., Moore, R.G., Cristofanilli, M., Lang, J.E., Khoury, J.D., Press, M.F., Kim, K.K., Khazan, N., and Zhang, Q. (2022). A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix\u00ae PC1 System. Cancers, 14.","DOI":"10.3390\/cancers14215238"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gra\u0161i\u010d Kuhar, C., Silvester, J., Mencinger, M., Ov\u010dari\u010dek, T., \u010cema\u017ear, M., Miceska, S., Modic, \u017d., Kuhar, A., Jesenko, T., and Kloboves Prevodnik, V. (2023). Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15133397"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Janning, M., Kobus, F., Babayan, A., Wikman, H., Velthaus, J.-L., Bergmann, S., Schatz, S., Falk, M., Berger, L.-A., and B\u00f6ttcher, L.-M. (2019). Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1\/PD-L1 Inhibitors. Cancers, 11.","DOI":"10.3390\/cancers11060835"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1373\/clinchem.2016.260299","article-title":"Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells","volume":"62","author":"Gorges","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41598-022-05502-6","article-title":"Copy Number Alterations Analysis of Primary Tumor Tissue and Circulating Tumor Cells from Patients with Early-Stage Triple Negative Breast Cancer","volume":"12","author":"Silvestri","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110500","DOI":"10.1016\/j.ygeno.2022.110500","article-title":"Comparative Analysis of Capture Methods for Genomic Profiling of Circulating Tumor Cells in Colorectal Cancer","volume":"114","author":"Alves","year":"2022","journal-title":"Genomics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1245\/s10434-021-11135-2","article-title":"Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer","volume":"29","author":"Ring","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108105","DOI":"10.1016\/j.celrep.2020.108105","article-title":"Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells","volume":"32","author":"Donato","year":"2020","journal-title":"Cell Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13058-022-01506-2","article-title":"Microtubule Disruption Reduces Metastasis More Effectively than Primary Tumor Growth","volume":"24","author":"Thompson","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41598-021-82068-9","article-title":"Gene Expression in Circulating Tumor Cells Reveals a Dynamic Role of EMT and PD-L1 during Osimertinib Treatment in NSCLC Patients","volume":"11","author":"Ntzifa","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_36","unstructured":"ANGLE plc (2023, September 28). Publications. Available online: https:\/\/angleplc.com\/publications\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.33393\/jcb.2023.2629","article-title":"Analytical Performance of the FDA-Cleared Parsortix\u00ae PC1 System","volume":"12","author":"Templeman","year":"2023","journal-title":"J. Circ. Biomark."},{"key":"ref_38","unstructured":"University Hospital, Basel, Switzerland (2023, January 01). Effect of Digoxin on Clusters of Circulating Tumor Cells (CTCs) in Breast Cancer Patients; Clinical Trial Registration NCT03928210, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03928210."},{"key":"ref_39","unstructured":"Institut Claudius Regaud (2023, January 01). Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients; Clinical Trial Registration NCT05988970, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05988970."},{"key":"ref_40","unstructured":"Centre Hospitalier Universitaire de N\u012bmes (2023, January 01). Proof-of-Concept Study of Blood Markers of Tumor Dissemination in Patients with versus without Intestinal Polyps, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05648240."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0038-1667085","article-title":"The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources","volume":"27","author":"Hays","year":"2018","journal-title":"Yearb. Med. Inform."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","article-title":"Genomic\u2013Transcriptomic Evolution in Lung Cancer and Metastasis","volume":"616","author":"Black","year":"2023","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2022.40.16_suppl.3077","article-title":"Use of Clinical RNA-Sequencing in the Detection of Actionable Fusions Compared to DNA-Sequencing Alone","volume":"40","author":"Michuda","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and Transcriptomic Profiling Expands Precision Cancer Medicine: The WINTHER Trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat. Med."},{"key":"ref_45","unstructured":"(2023, September 29). Analyzing Tumor RNA to Improve Cancer Precision Medicine\u2014NCI, Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/tumor-rna-cancer-precision-medicine."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bulcan.2021.12.005","article-title":"En marche vers une oncologie personnalis\u00e9e: L\u2019apport des techniques g\u00e9nomiques et de l\u2019intelligence artificielle dans l\u2019usage des biomarqueurs tumoraux circulants","volume":"109","author":"Perrier","year":"2022","journal-title":"Bull. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","article-title":"Liquid Biopsy and Tumor Heterogeneity in Metastatic Solid Tumors: The Potentiality of Blood Samples","volume":"39","author":"Russano","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-17-2092","article-title":"Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer","volume":"24","author":"Rossi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Alama, A., Coco, S., Genova, C., Rossi, G., Fontana, V., Tagliamento, M., Dal Bello, M.G., Rosa, A., Boccardo, S., and Rijavec, E. (2019). Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. J. Clin. Med., 8.","DOI":"10.3390\/jcm8071011"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.21037\/tlcr.2016.10.02","article-title":"Circulating Tumor Cells versus Circulating Tumor DNA in Lung Cancer-Which One Will Win?","volume":"5","author":"Camps","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Aoki, M., Shoji, H., Kashiro, A., Takeuchi, K., Shimizu, Y., and Honda, K. (2020). Prospects for Comprehensive Analyses of Circulating Tumor Cells in Tumor Biology. Cancers, 12.","DOI":"10.3390\/cancers12051135"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/cas.14092","article-title":"Monitoring of Cancer Patients via Next-Generation Sequencing of Patient-Derived Circulating Tumor Cells and Tumor DNA","volume":"110","author":"Onidani","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-Exome Sequencing of Cell-Free DNA and Circulating Tumor Cells in Multiple Myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85349","DOI":"10.18632\/oncotarget.13350","article-title":"Enumeration and Targeted Analysis of KRAS, BRAF and PIK3CA Mutations in CTCs Captured by a Label-Free Platform: Comparison to CtDNA and Tissue in Metastatic Colorectal Cancer","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1878-0261.12540","article-title":"PIK3CA Hotspot Mutations in Circulating Tumor Cells and Paired Circulating Tumor DNA in Breast Cancer: A Direct Comparison Study","volume":"13","author":"Tzanikou","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Keup, C., Suryaprakash, V., Storbeck, M., Hoffmann, O., Kimmig, R., and Kasimir-Bauer, S. (2021). Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. Cells, 10.","DOI":"10.3390\/cells10020212"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13073-021-00902-1","article-title":"Integrative Statistical Analyses of Multiple Liquid Biopsy Analytes in Metastatic Breast Cancer","volume":"13","author":"Keup","year":"2021","journal-title":"Genome Med."},{"key":"ref_58","unstructured":"Li, K. (2023, August 09). Application of the Detection of Circulating Tumor Cell and Circulating Tumor DNA in the Diagnosis of Metastasis in Gastric Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05208372."},{"key":"ref_59","unstructured":"Jonsson Comprehensive Cancer Center (2023, August 09). A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03902951."},{"key":"ref_60","unstructured":"Zhao, J. (2023, August 09). Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Patients with Resectable or Locally Advanced Gastric or Gastro-Oesophageal Junction Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03957564."},{"key":"ref_61","unstructured":"Lygre, K.B. (2023, August 09). Open D3 Right Colectomy Compared to Laparoscopic CME Right Colectomy for Right Sided Colon Cancer; an Open Randomized Controlled Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03776591."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Markou, A.N., Londra, D., Stergiopoulou, D., Vamvakaris, I., Potaris, K., Pateras, I.S., Kotsakis, A., Georgoulias, V., and Lianidou, E. (2023). Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-CfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15061877"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13148-022-01283-x","article-title":"DNA Methylation Analysis of Tumor Suppressor Genes in Liquid Biopsy Components of Early Stage NSCLC: A Promising Tool for Early Detection","volume":"14","author":"Markou","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ntzifa, A., Londra, D., Rampias, T., Kotsakis, A., Georgoulias, V., and Lianidou, E. (2021). DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. Cancers, 13.","DOI":"10.3390\/cancers13235974"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1002\/1878-0261.13094","article-title":"Clinical Potential of Circulating Free DNA and Circulating Tumour Cells in Patients with Metastatic Non-Small-Cell Lung Cancer Treated with Pembrolizumab","volume":"15","author":"Anido","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ntzifa, A., Kotsakis, A., Georgoulias, V., and Lianidou, E. (2021). Detection of EGFR Mutations in Plasma CfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. Cancers, 13.","DOI":"10.3390\/cancers13112736"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.esmoop.2021.100086","article-title":"Blood-Based Genomics of Triple-Negative Breast Cancer Progression in Patients Treated with Neoadjuvant Chemotherapy","volume":"6","author":"Ortolan","year":"2021","journal-title":"ESMO Open"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mondelo-Mac\u00eda, P., Rodr\u00edguez-L\u00f3pez, C., Vali\u00f1a, L., Agu\u00edn, S., Le\u00f3n-Mateos, L., Garc\u00eda-Gonz\u00e1lez, J., Abalo, A., Rapado-Gonz\u00e1lez, O., Su\u00e1rez-Cunqueiro, M., and D\u00edaz-Lagares, A. (2020). Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients. Cells, 9.","DOI":"10.3390\/cells9020522"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gorges, K., Wiltfang, L., Gorges, T.M., Sartori, A., Hildebrandt, L., Keller, L., Volkmer, B., Peine, S., Babayan, A., and Moll, I. (2019). Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers, 11.","DOI":"10.3390\/cancers11111685"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41416-020-0750-9","article-title":"Detection and Prognostic Role of Heterogeneous Populations of Melanoma Circulating Tumour Cells","volume":"122","author":"Morici","year":"2020","journal-title":"Br. J. Cancer"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/1\/50\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:48:43Z","timestamp":1760104123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/1\/50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cimb46010050"],"URL":"https:\/\/doi.org\/10.3390\/cimb46010050","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]}}}